ArticleClinical cancer research : an official journal of the American Association for Cancer Research2025

FDA Approval Summary: Ivosidenib for Treatment of Adult Patients with Relapsed/Refractory Myelodysplastic Syndrome with an IDH1 Mutation.

Ashley C Woods et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.